Most Read Articles
Pearl Toh, 15 Feb 2019
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Stephen Padilla, 06 Feb 2019
Alirocumab has prevented nonfatal cardiovascular events and deaths, the total of which is twice the number of first events prevented among patients with acute coronary syndrome (ACS) over a median follow-up of 2.8 years, according to results of the ODYSSEY OUTCOMES* trial. In addition, a robust association is seen between the risks of nonfatal and fatal events during the study.
14 Sep 2017
Rifaximin appears to confer increased survival benefit in hepatic encephalopathy patients without hepatocellular carcinoma (HCC), in addition to reducing the risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent hepatic encephalopathy, according to a study.
18 Jan 2019
Azithromycin treatment in children with recurrent asthma-like symptoms acutely disrupts gut microbiota composition, a recent study has found.

Biosimilar CT-P13 on par with infliximab in Crohn’s Disease

06 Feb 2019

CT-P13 is as effective as its reference product (RP) infliximab for infliximab-naïve patients with Crohn’s disease (CD), suggests a recent study. Safety outcomes are also comparable between the two drugs.

The composite endpoint of death, CD-related surgery, all-cause hospitalization and reimbursement of another biologic therapy present in a total of 1,147 patients in the RP group and 952 in the CT-P13 group, as well as 838 and 719 hospitalizations, respectively.

Multivariable analysis revealed that CT-P13 was on a par with RP (HR, 0.92; 95 percent CI, 0.85–0.99). There were no between-group differences observed in safety outcomes: serious infections (HR, 0.82; 0.61–1.11), tuberculosis (HR, 1.10; 0.36–3.34), and solid or haematologic cancer (HR, 0.66; 0.33–1.32).

This comparative equivalence cohort study included 5,050 infliximab-naïve CD patients aged >15 years, who had started treatment with RP (n=2,551) or CT-P13 (n=2,400) and had no other indications for infliximab. Equivalence was defined as a 95 percent CI of the HR of CT-P14 vs RP in a multivariable marginal Cox model situated within prespecified margins (0.80–1.25).

The study was limited by incomplete clinical data from the Système National des Données de Santé, a French nationwide health administrative database (1 March 2015 to 30 June 2017).

“CT-P13 is a biosimilar of the RP infliximab, with demonstrated efficacy and safety for some inflammatory arthritides. It was approved for the treatment of CD on that basis, without specific studies examining its effects in CD,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 15 Feb 2019
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Stephen Padilla, 06 Feb 2019
Alirocumab has prevented nonfatal cardiovascular events and deaths, the total of which is twice the number of first events prevented among patients with acute coronary syndrome (ACS) over a median follow-up of 2.8 years, according to results of the ODYSSEY OUTCOMES* trial. In addition, a robust association is seen between the risks of nonfatal and fatal events during the study.
14 Sep 2017
Rifaximin appears to confer increased survival benefit in hepatic encephalopathy patients without hepatocellular carcinoma (HCC), in addition to reducing the risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent hepatic encephalopathy, according to a study.
18 Jan 2019
Azithromycin treatment in children with recurrent asthma-like symptoms acutely disrupts gut microbiota composition, a recent study has found.